Home › Healthcare › Genetic Signatures (ASX:GSS)

Microba funding shortfall leaves proposed GSS transaction abandoned

Healthcare By Ada Torres 2 min read

Genetic Signatures has ended its proposed merger with Microba Life Sciences after Microba said it could not complete the transaction without raising more capital. The decision also removes the deal’s shareholder vote and leaves a Takeovers Panel application awaiting clarification.

  • Proposed Microba merger will not proceed
  • Microba said additional capital was required to complete the transaction
  • GSS declined to provide unsecured working capital funding
  • Resolution 4 will be withdrawn from the 30 November AGM
  • Further update on the Takeovers Panel application is pending

Funding Constraint Ends Proposed Merger

Genetic Signatures Limited (ASX:GSS) has abandoned its proposed merger with Microba Life Sciences Limited (ASX:MAP), ending months of discussions, due diligence and negotiations after Microba told the market it lacked the financial capacity to complete the deal without additional capital.

GSS said its board had resolved not to proceed after considering Microba’s position. The decision follows the companies’ revised merger terms and a proposed all-scrip transaction that had been put before GSS shareholders, while the earlier process had already drawn a formal challenge from BCAL Diagnostics through the Takeovers Panel.

Microba’s funding position was not the only obstacle. GSS said it had discussed providing unsecured debt funding to help meet Microba’s working capital requirements during implementation, but the GSS board ultimately decided not to proceed because of the associated risks and potential regulatory requirements.

AGM Vote and Takeovers Panel Process Now in Question

The immediate corporate consequence is the withdrawal of Resolution 4 from GSS’s annual general meeting agenda for 30 November. That resolution was tied to the proposed transaction, which had contemplated the issue of new GSS securities to support the merger.

The termination also changes the setting for BCAL Diagnostics’ Takeovers Panel application, lodged on 13 November. The filing does not state what effect the collapsed transaction will have on that application; GSS said it will make a further announcement after assessing the position.

For GSS, the failed deal removes a major strategic transaction from the near-term agenda, but the announcement does not quantify any termination costs or other financial impact. The next disclosures will therefore matter less for the mechanics of a vote than for what remains of the dispute, including the formal withdrawal of Resolution 4 and the status of the Takeovers Panel process.

Bottom Line?

The merger is off, but the governance questions around the transaction are not fully resolved until GSS clarifies the Takeovers Panel application and any financial consequences.

Questions in the middle?

  • Will the Takeovers Panel application continue after the proposed merger is withdrawn?
  • Will GSS disclose any costs or other financial effects from ending the transaction?
  • How will Microba address the additional capital requirement that prevented completion of the merger?

Sources